GCG and chronic kidney disease: Cardiovascular risks are common within diabetic patients with CKD, when such risk jeopardize the wellbeing of the patient, SGLT2i, finerenone and GLP-1 analogues are all apposite recommendations, but when the risk of renal events heightens, then SGLT2i will be the sole recommendation available.